In summary, these data indicate that aberrant liver basement membrane responses are associated with worsening fibrosis, low hepatic FXR activity, and adverse clinical outcomes in patients with MASLD. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.